PTC Therapeutics Inc. diskutieren
PTC Therapeutics Inc.
WKN: A1W0MW / Symbol: PTCT / Name: PTC Therapeutics / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
?
1,61 %
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at UBS Group AG from $71.00 to $80.00. They now have a "buy" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Cantor Fitzgerald from $112.00 to $120.00. They now have an "overweight" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Wells Fargo & Company from $74.00 to $78.00. They now have an "overweight" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Bank of America Corporation from $68.00 to $84.00. They now have a "buy" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Truist Financial Corporation from $80.00 to $86.00. They now have a "buy" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its "outperform" rating re-affirmed by analysts at Royal Bank Of Canada.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Wells Fargo & Company from $78.00 to $79.00. They now have an "overweight" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics (NASDAQ:PTCT) had its price target lowered by analysts at Bank of America Corporation from $82.00 to $76.00. They now have a "buy" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics (NASDAQ:PTCT) had its price target lowered by analysts at Morgan Stanley from $76.00 to $71.00. They now have an "overweight" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics (NASDAQ:PTCT) had its price target lowered by analysts at Wells Fargo & Company from $79.00 to $73.00. They now have an "overweight" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics (NASDAQ:PTCT) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $118.00 price target on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics (NASDAQ:PTCT) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $73.00 price target on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics (NASDAQ:PTCT) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics (NASDAQ:PTCT) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics (NASDAQ:PTCT) had its price target raised by analysts at Royal Bank Of Canada from $70.00 to $82.00. They now have an "outperform" rating on the stock.
Ratings data for PTCT provided by MarketBeat
Neueste Beiträge
Citigroup_Inc_ in Northrop Grumman Corp. diskutieren